The firm, which plans to use the ticker symbol "MAZE" on the Nasdaq, develops drugs designed to mimic the protective effects ...

Researchers from the Broad Institute, Mass General, Stanford, and elsewhere are investigating why patients with South Asian ...

The agency affirmed the use of biopsies for biomarker-driven trials but cautioned against optional biopsies that offer little value to the patient or trial.

The already crowded field of biomarker-targeted drugs is poised to only get busier with new biomarkers, ADCs, and cancer vaccines.

The changes will result in one company focused exclusively on cancer cell therapies and another on strategic transactions to build a pipeline of innovative medicines.

The investment will be used to help increase enrollment of follicular lymphoma patients in an ongoing Phase I study of Verismo's KIR-CAR therapy.

The company will use the proceeds to test its gene therapy XC001 in two Phase II studies involving patients with cardiovascular disease.